Evidence map›Paper›PMID 35121856›Full record

ArticleNature protocols2022

A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus.

Hamed Ekhtiari, Mehran Zare-Bidoky, Arshiya Sangchooli, Amy C Janes, Marc J Kaufman, Jason A Oliver, James J Prisciandaro, Torsten Wüstenberg, Raymond F Anton, Patrick Bach and 50 more

Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
In one paragraph

Article in Nature protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06308484 (Neuromodulation and Mindfulness as Therapeutic Treatment in Detoxified Patients With AUD), which is not on this map. Cited by 54 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 6 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06308484 narecruitingnot on this mapstarted 2024, after this paper: background citation

Neuromodulation and Mindfulness as Therapeutic Treatment in Detoxified Patients With AUD

TypeinterventionalSponsorCharite University, Berlin, GermanyRan2024 to 2027Enrolled140ConditionsAlcohol DependenceArmsTranscutaneous vagus nerve stimulation, Closed-loop AM-tACS
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 6 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Digitalized transcranial electrical stimulation: A consensus statement.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2022
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. The neurobiological cravings signature (NCS) as a predictive neuromarker of clinical outcomes in alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

60 authors at 20 institutions in 9 countries.

Hamed EkhtiariLaureate Institute for Brain Research, Tulsa, OK, USA. hekhtiari@laureateinstitute.org.ORCID http://orcid.org/0000-0001-6902-8798
Mehran Zare-Bidoky *Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-2572-8498
Arshiya Sangchooli *Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Amy C JanesDepartment of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Marc J KaufmanDepartment of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Jason A OliverDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
James J PrisciandaroDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Torsten WüstenbergDepartment of Psychiatry and Neurosciences, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Raymond F AntonDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Patrick BachDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Heidelberg University, Mannheim, Germany.
Alex BaldacchinoDivision of Population Studies and Behavioural Sciences, St Andrews University Medical School, University of St Andrews, Scotland, UK.
Anne BeckDepartment of Psychiatry and Neurosciences, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
James M BjorkDepartment of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
Judson BrewerDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA.
Anna Rose ChildressPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Eric D ClausDepartment of Biobehavioral Health, The Pennsylvania State University, University Park, PA, USA.
Kelly E CourtneyDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Mohsen EbrahimiIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-9197-3750
Francesca M FilbeyCenter for BrainHealth, School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX, USA.
Dara G GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Peyman Ghobadi AzbariIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Rita Z GoldsteinDepartments of Psychiatry & Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anna E GoudriaanDepartment of Psychiatry, Amsterdam University Medical Center, University of Amsterdam and Amsterdam Neuroscience, Amsterdam, The Netherlands.
Erica N GrodinDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
J Paul HamiltonCenter for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Colleen A HanlonDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Peyman Hassani-AbharianBrain and Cognition Clinic, Institute for Cognitive Science Studies, Tehran, Iran.
Andreas HeinzDepartment of Psychiatry and Neurosciences, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-5405-9065
Jane E JosephDepartment of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.
Falk KieferDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Heidelberg University, Mannheim, Germany.
Arash Khojasteh ZonooziIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Hedy KoberDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Rayus KuplickiLaureate Institute for Brain Research, Tulsa, OK, USA.
Qiang LiDepartment of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3577-7808
Joseph McClernonDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
Hamid R NooriInternational Center for Primate Brain Research, Center for Excellence in Brain Science and Intelligence Technology (CEBSIT)/Institute of Neuroscience (ION), Chinese Academy of Sciences, Shanghai, China.
Max M OwensDepartment of Psychiatry, University of Vermont, Burlington, VT, USA.
Martin P PaulusLaureate Institute for Brain Research, Tulsa, OK, USA.
Irene PeriniCenter for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0002-5972-0913
Marc PotenzaDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6323-1354
Stéphane PotvinCentre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, University of Montreal, Montreal, Canada.
Lara RayDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Joseph P SchachtUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0003-4250-0495
Dongju SeoDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Rajita SinhaDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Michael N SmolkaDepartment of Psychiatry, Technische Universität Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0001-5398-5569
Rainer SpanagelInstitute of Psychopharmacology, Central Institute of Mental Health, Mannheim, Germany.
Vaughn R SteeleDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
Elliot A SteinIntramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA.
Sabine Steins-LoeberDepartment of Clinical Psychology and Psychotherapy, Otto-Friedrich-University of Bamberg, Bamberg, Germany.ORCID http://orcid.org/0000-0002-7651-0627
Susan F TapertDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Antonio Verdejo-GarciaTurner Institute for Brain and Mental Health, Monash University, Clayton, Australia.ORCID http://orcid.org/0000-0001-8874-9339
Sabine Vollstädt-KleinDepartment of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0002-6210-672X
Reagan R WetherillPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1991-6292
Stephen J WilsonDepartment of Psychology, The Pennsylvania State University, University Park, PA, USA.
Katie WitkiewitzDepartment of Psychology, University of New Mexico, Albuquerque, NM, USA.
Kai YuanSchool of Life Science and Technology, Xidian University, Xi'an, China.
Xiaochu ZhangDepartment of Psychology, School of Humanities and Social Science, University of Science and Technology of China, Anhui, China.ORCID http://orcid.org/0000-0002-7541-0130
Anna ZilverstandDepartment of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-4889-9700
Yale University · USUniversity of California, Los Angeles · USCharité - Universitätsmedizin Berlin · DEHeidelberg University · DEMedical University of South Carolina · USDuke University · USHarvard University · USLaureate Institute for Brain Research · USLinköping University · SEPennsylvania State University · USTehran University of Medical Sciences · IRUniversity of California San Diego · USUniversity of Minnesota · USUniversity of Pennsylvania · USAir Force Medical University · CNAmsterdam Neuroscience · NLBrown University · USCentral Institute of Mental Health · DEIcahn School of Medicine at Mount Sinai · USInstitute for Cognitive Science Studies · IR

Funding

ABCD-USA Consortium: Coordinating CenterU24DA041147 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANDRA A BROWN, TERRY L. JERNIGAN · 2015 to 2026
$54.7M
TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Patrick J. Mulholland · 1996 to 2026
$46.8M
ABCD-USA Consortium: Research ProjectU01DA041089 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Joanna Jacobus, Susan F. Tapert · 2015 to 2026
$31.7M
Viral Innovation CoreP30DA048742 · NIDA · UNIVERSITY OF MINNESOTA · PI Mark John Thomas · 2020 to 2026
$19.0M
SUBSTANCE ABUSEK12DA000167 · NIDA · YALE UNIVERSITY · PI STEPHANIE S O'MALLEY, Marc N Potenza · 1991 to 2026
$17.7M
National Consortium on Alcohol and NeuroDevelopment in Adolescence: San DiegoU01AA021692 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Susan F. Tapert · 2012 to 2026
$11.8M
Defining neurobiological links between substance use and mental illnessZIADA000641 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI JANES, AMY · 2022 to 2025
$8.8M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
National Consortium on Alcohol and NeuroDevelopment in Adolescence (NCANDA): Administrative ResourceU24AA021695 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANDRA A BROWN, Susan F. Tapert · 2016 to 2026
$6.0M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addictionR01AT010627 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2019 to 2023
$3.8M
Neural Mechanisms of Behavior Change in a Community Sample of DrinkersR01AA023665 · NIAAA · THE MIND RESEARCH NETWORK · PI CLAUS, ERIC D, WITKIEWITZ, KATIE A · 2015 to 2019
$3.6M
NCCIH NIH HHS R01 AT010627NHLBI NIH HHS R21 HL144673NIAAA NIH HHS F32 AA027699NIAAA NIH HHS K08 AA023545NIAAA NIH HHS K23 AA023894NIAAA NIH HHS P50 AA010761NIAAA NIH HHS R01 AA022328NIAAA NIH HHS R01 AA023665NIAAA NIH HHS R01 AA025365NIAAA NIH HHS R01 AA026844NIAAA NIH HHS R01 AA026859NIAAA NIH HHS R01 AA027765NIAAA NIH HHS U01 AA021692NIAAA NIH HHS U24 AA021695NIDA NIH HHS K02 DA042987NIDA NIH HHS K12 DA000167NIDA NIH HHS K23 DA042898NIDA NIH HHS P30 DA048742NIDA NIH HHS R01 DA030344NIDA NIH HHS R01 DA039135NIDA NIH HHS R01 DA040670NIDA NIH HHS R01 DA041438NIDA NIH HHS R01 DA041528NIDA NIH HHS R01 DA041866NIDA NIH HHS R01 DA047851NIDA NIH HHS R01 DA048301NIDA NIH HHS R01 DA049547NIDA NIH HHS R01 DA053342NIDA NIH HHS R01 DA054275NIDA NIH HHS R21 DA044465NIDA NIH HHS R21 DA045853NIDA NIH HHS T32 DA024635NIDA NIH HHS U01 DA041089NIDA NIH HHS U24 DA041147NIDA NIH HHS UG1 DA050209
6 · The paper itself

Abstract

Cue reactivity is one of the most frequently used paradigms in functional magnetic resonance imaging (fMRI) studies of substance use disorders (SUDs). Although there have been promising results elucidating the neurocognitive mechanisms of SUDs and SUD treatments, the interpretability and reproducibility of these studies is limited by incomplete reporting of participants' characteristics, task design, craving assessment, scanning preparation and analysis decisions in fMRI drug cue reactivity (FDCR) experiments. This hampers clinical translation, not least because systematic review and meta-analysis of published work are difficult. This consensus paper and Delphi study aims to outline the important methodological aspects of FDCR research, present structured recommendations for more comprehensive methods reporting and review the FDCR literature to assess the reporting of items that are deemed important. Forty-five FDCR scientists from around the world participated in this study. First, an initial checklist of items deemed important in FDCR studies was developed by several members of the Enhanced NeuroImaging Genetics through Meta-Analyses (ENIGMA) Addiction working group on the basis of a systematic review. Using a modified Delphi consensus method, all experts were asked to comment on, revise or add items to the initial checklist, and then to rate the importance of each item in subsequent rounds. The reporting status of the items in the final checklist was investigated in 108 recently published FDCR studies identified through a systematic review. By the final round, 38 items reached the consensus threshold and were classified under seven major categories: 'Participants' Characteristics', 'General fMRI Information', 'General Task Information', 'Cue Information', 'Craving Assessment Inside Scanner', 'Craving Assessment Outside Scanner' and 'Pre- and Post-Scanning Considerations'. The review of the 108 FDCR papers revealed significant gaps in the reporting of the items considered important by the experts. For instance, whereas items in the 'General fMRI Information' category were reported in 90.5% of the reviewed papers, items in the 'Pre- and Post-Scanning Considerations' category were reported by only 44.7% of reviewed FDCR studies. Considering the notable and sometimes unexpected gaps in the reporting of items deemed to be important by experts in any FDCR study, the protocols could benefit from the adoption of reporting standards. This checklist, a living document to be updated as the field and its methods advance, can help improve experimental design, reporting and the widespread understanding of the FDCR protocols. This checklist can also provide a sample for developing consensus statements for protocols in other areas of task-based fMRI.

Indexed as

ChecklistMagnetic Resonance ImagingCuesDelphi TechniqueHumansReproducibility of Results

Identifiers

PMID35121856
PMCPMC9063851
OpenAlexW4213300278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.